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A B S T R A C T
Introduction: Lacosamide (LCS) is a new antiepileptic drug (AED) licensed in the European Union (EU) and
United States (US) in 2008.
Aims: To evaluate the efﬁcacy and tolerability of add-on LCS in an out-patient epilepsy clinic setting to
obtain useful information for everyday practice.
Methods: We pooled data retrospectively from the case note of patients with refractory epilepsy in
whom LCS had been prescribed in 19 hospitals across the United Kingdom.
Results: Four hundred and three patients were included (mean age 41.9 years, 50.6% women, 18.1% with
learning disabilities (LD)). Mean follow-up (FU) was 11.6 months (range one day to 42 months). Most
patients (86.9%) presented with symptomatic partial epilepsy (SPE) and 80% were taking two or more
antiepileptic drugs (AEDs) when LCS was added (mean 2, range 0–4). Retention rates were 80% at six
months, 68% at one year and 45% at two years. The efﬁcacy of LCS was evaluated at three months and at
the ﬁnal FU. At three months one hundred and eight patients (31.1%) reported 50% seizure reduction
and 32 (9.2%) were seizure free. At the ﬁnal FU 102 (37.5%) reported 50% seizures reduction and 28
(9.8%) were seizure free.
One hundred and ninety three patients (48.7%) reported adverse effects (AEs). The most frequent
were sedation and dizziness, followed by nausea. Lacosamide was discontinued in 150 patients (38%), 60
due to AEs alone.
Conclusion: LCS appears to be an effective and safe AED when used as adjunctive therapy in patients with
refractory partial epilepsy.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Lacosamide (LCS) is a new adjunctive drug licensed for the
treatment of focal seizures with or without secondary generalisa-
tion in patients with epilepsy aged 16 years and older. Lacosamide
was approved in the member states of the European Union in
September 2008 and in the United States in October 2008.* Corresponding author at: Department of Neurology, King’s College Hospital
NHS Foundation Trust, London SE5 9RS, UK. Tel.: +44 203 299 8339;
fax: +44 203 299 8341.
E-mail address: Robert.Elwes@nhs.net (R. Elwes).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.05.005Lacosamide has a novel mechanism of action producing selective
enhancement of sodium channel slow inactivation.1 In addition to
the treatment of epilepsy, LCS has also been found to be useful in
the treatment of pain in diabetic neuropathy.2
Three randomised, multicentre, double blind, placebo-con-
trolled trials of LCS have shown a major reduction in seizure
frequency at three different doses with responder rates ranging
from 32.7% to 35% for 200 mg/day, 38.3% to 41.1% for 400 mg/day
and 38.1% to 41.2% for 600 mg/day. With placebo the responder
rates in those studies ranged from 18.3% to 25.8%.3–5 Four post-
marketing studies have been published, including one from the
United Kingdom (UK), showing a high response rate and good
tolerability.6–9 We present the clinical experience with lacosamidevier Ltd. All rights reserved.
L. Flores et al. / Seizure 21 (2012) 512–517 513in 403 patients from nineteen centres in the UK, the largest post
marketing group studied to date.
2. Methods
Data were obtained from the case notes between August 2010
and August 2011 from nineteen hospitals across the UK.
Identiﬁcation of patients and collection of data were coordinated
from two sites in Leeds (N = 287) and London (N = 116). The same
data collection sheet was used at both centres and the principal
outcomes were based on the combined data. At the London centre
more detailed information on concomitant medication and drug
changes during the course of the study were also available and a
further analysis relating to drug combinations was carried out in
this subgroup. Both sites recruited cases from specialist epilepsy
centres and the two groups of patents did not differ in terms of
clinical features or outcomes. Cases were identiﬁed through
electronic medical and pharmacy records of patients who had been
prescribed LCS. Patients included were adults attending their usual
specialist epilepsy clinic appointments and the decision to use LCS
was based on the treating clinician’s recommendation. Data were
obtained by reviewing medical notes and electronic clinical letters.
An electronic database was set up.
All patients in whom lacosamide have been prescribed were
included even if they took the drug for a short period of a few days.
The only exclusion criteria was the lack of follow up. Data
included: demographic details such as age and sex, clinical features
such as the presence of LD, epilepsy syndrome, seizure types and
frequency, drug details: concomitant and previous AEDs, any
change in other AEDS while on LCS, maximum doses of LCS, length
of exposure to LCS, adverse effects (AEs) and withdrawal rates.
Patients were usually seen in clinic every 3–6 months. Frequency
of seizures was obtained directly from what was recorded in the
medical notes, or seizure diaries. Providers usually documented the
number of seizures each month or recorded an average per month
since the last time they saw the patient. If the numerical change in
seizures was not recorded then those that improved were assessed
as having less than 50% reduction in seizure frequency.
Outcome following treatment was deﬁned and determined as
follows.
Seizure free: terminal remission of 3 months or more.
50% or more reduction: a reduction in frequency of seizures of
50% or more in the last 3 months of follow-up compared to a
retrospective 3 month baseline. Only cases where seizure
frequency was accurately recorded were placed in this group.
Less than 50% reduction: a reduction of between 1 and 49% in
the last 3 months of follow-up compared to a 3-month baseline. A
minority of cases recorded as having a qualitative improvement
but speciﬁc numbers of seizures were not recorded were also
placed in this group.
No response and worsening of seizures: this was most often
based a qualitative or overall clinical assessment from clinic letters
rather than numerical measurements of seizure frequency.
Two response rates were determined. The ﬁrst was based on the
seizure frequency in the ﬁrst three months after commencing LCS;
the second on that in the three months prior to the latest follow-up.
The second response rate was only determined for those patients
with a minimum of six months FU. Retention time on LCS was
estimated using Kaplan–Meier survival curves and Chi-square
proportion tests were applied.
3. Results
A total of 403 patients who had at least one follow up were
included. Gender distribution was roughly equal (males 199,
females 204) with age ranging between 17 and 82 years (mean41.9). Three hundred and seventy two were classiﬁed symptomatic
or cryptogenic partial epilepsy, 13 idiopathic generalised epilepsy,
7 symptomatic generalised epilepsy and 11 were unclassiﬁed. The
mean number of concomitant AED was 2.29, range 0–4; 80% of
patients were taking two or more (Table 1). Learning disability (LD)
was present in 73 (18.1%).
The initial daily dose of LCS varied between 25 mg and 200 mg,
50 mg/day being the most frequent (70%) with variable weekly or
two weekly increments and a target tailored to each patient
according to clinician judgement. The mean maximum dose was
279.4 mg/day, ranging from 25 to 700.
3.1. Follow-up and outcome
The length of exposure to LCS ranged from one day to 42
months with a mean of 11.6 months. Retention time, deﬁned as the
probability of remaining on treatment with LCS, was assessed
using Kaplan–Meier survival curves (Fig. 1). The probability of
remaining on LCS for all patients was 80% at six months, 68% at one
year, 58% at 18 months and 45% at two years. In patients with LD,
these ﬁgures were 78% at six months, 63% at one year, and 45% at
18 months and two years.
The ﬁrst outcome was measured at three months FU. Of the
initial 403 patients identiﬁed 46 (11.4%) had already discontinued
LCS, mainly due to AEs, and ten had less than three months of
exposure by the end of the study. Thus, 347 (86.1%) could be
included in the analysis. Of these, 108 (31.1%) reported 50%
reduction of seizures, including 32 (9.2%) SF; 98 (28.2%) had less
than 50% of reduction; 50 (14.4%) had an increase in seizures; 91
(26.2%) were unchanged (i.e. no response) (See Table 2).
The second outcome was based on the seizure frequency in the
last three months of follow-up. The mean FU was 15 months (range
6–42). Among 285 patients with more than six months follow-up,
102 (35.7%) had 50% reduction in seizures, of whom 28 (9.8%)
were SF; 62 (21.7%) had a reduction of less than 50%, 53 (18.6%) had
an increase in their frequency of seizures and 68 (23.8%) did not
respond. Most patients who were initially seizure free were seizure
free for the last three months. Two patients were seizure free for
seven months, one for nine and one for 15. Three patients who
underwent surgery for their epilepsy reported being seizure free
postoperatively; two had reported less than 50% reduction of
seizures while on LCS before surgery, and one had not responded to
LCS before surgery.
Patients with LD had a slightly lower response rate at 50%
reduction of seizures and rates of SF at ﬁnal FU than patients
without LD, but this difference was not signiﬁcant: 32.7%
compared to 36.5% (Chi-squared = 0.048, p = 0.8272), and 5.4%
versus 10.8% (Chi-squared = 0.741, p = 0.3894) respectively.
The efﬁcacy of LCS was also assessed in three seizures types:
GTC, CPS, and SPS. The highest seizure reduction and seizure
freedom rates were seen in tonic clonic seizures (see Tables 2 and
3).
At three months follow-up the mean maximum dose of LCS in
responder patients (50% reduction of seizures) was 291.4 mg/day
(range = 100–700), in seizure free patients was 256.5 mg/day
(range = 100–400), in partial responder patients was 314.1 mg/day
(range = 25–600) and in non-responder patients was 295.6 mg/day
(range = 50–650). At the ﬁnal follow-up these doses were
310.8 mg/day (range = 100–700), 251.8 mg/day (range = 100–
450), 322.3 mg/day (range = 100–600) and 304.2 mg/day
(range = 100–600), respectively.
3.2. Adverse effects and withdrawal
Adverse effects were reported in 193 (48.7%) patients. The most
frequent were sedation in 89 patients, dizziness in 73, nausea and
Table 1
Clinical features of all 403 patients and outcome at ﬁnal follow up in 285 patients with 6 months of more follow-up.
Characteristic Total number/number
with 6 months FU
Outcome of seizures at the last FU (285 patients with 6 months FU)
>50% reduction including SF patients <50% reduction Patients seizure free Non responder Increase
N (%) N (%) N (%) N (%) N (%)
Age
17–30 98/68 22 (32.4) 16 (23.5) 4 (5.8) 16 (23.5) 14 (20.6)
31–50 202/143 50 (34.9) 30 (20.9) 14 (9.7) 36 (25.1) 27 (18.9)
51–82 103/74 30 (40.5) 16 (21.6) 10 (13.5%) 16 (21.6) 12 (16.2)
LD
Yes 73/55 18 (32.7) 13 (23.6) 3 (5.4) 13 (23.6) 11 (20)
No 330/230 84 (36.5) 49 (21.3) 25 (10.8) 55 (23.9) 42 (18.2)
Gender
Male 199/148 51 (34.4) 28 (18.9) 12 (8.1) 31 (20.9) 38 (25.6)
Female 204/137 51 (37.2) 34 (24.8) 16 (11.6) 37 (27) 15 (10.9)
Syndrome
IGE 13/9 3 (33.3) 1 (11.1) 3 (33.3) 3 (33.3) 2 (22.2)
SGE 7/5 3 (60) 1 (20) 0 (0) 0 (0) 1 (20)
SPE 372/263 94 (35.7) 58 (22.1) 24 (9.1) 64 (24.3) 47 (17.8)
UC 11/8 2 (25) 2 (25) 1 (12.5) 1 (12.5) 3 (37.5)
Concomitant drugs
1 83/51 19 (37.2) 12 (23.5) 6 (11.7) 13 (25.5) 7 (13.7)
2 158/117 47 (40.1) 27 (23.1) 11 (9.4) 28 (23.9) 15 (12.8)
3+ 162/117 36 (30.7) 23 (19.6) 11 (9.4) 27 (23.1) 31 (26.4)
Exposure to LCS/months
<3.0 56
3.0–5.9 62
6.0–11.9 96 26 (27.1) 16 (16.6) 10 (14.4%) 33 (34.3) 21 (21.8)
12.0–17.9 94 35 (37.2) 19 (20.2%) 11 (11.7%) 24 (25.5) 16 (17)
18.0–23.9 57 24 (42.1) 17 (29.8%) 3 (5.3%) 8 (14) 8 (14)
>24.0 38 17 (44.7) 10 (26.3%) 4 (10.5% 3 (7.8) 8 (21)
All cases 403/285 102 (35.7) 62 (21.7) 28 (9.8%) 68 (23.8) 53 (18.5)
FU, follow-up; LD learning difﬁculties; IGE, idiopathic generalised epilepsy; SGE, Symptomatic generalised epilepsy; UC, unclassiﬁed.
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double or blurred vision in 42, headache in 32, and skin irritation in
13. Other less frequent side effects are listed in Table 4.
One hundred and ﬁfty (38%) patients out of 403 discontinued
LCS. The average retention time in those patients was 7.2 months.
Of those 150 patients, 84 (20.8%) withdrew mostly due to
intolerable AEs, 35(8.7%) due to lack of efﬁcacy only, 10 (2.5%)
due to increase in seizure frequency and 10 (2.5%) because of
increase in seizure severity. In 11 (2.7%) the cause was not stated.
Of the 84 patients with intolerable AEs, four also had increased
seizure frequency and 20 lack of efﬁcacy. The most frequent AEs in
those patients withdrawing LCS were somnolence, dizziness,
unsteadiness, double vision, headache, nausea, other gastrointes-
tinal disturbances and increase in seizure frequency.Fig. 1. Actuarial probability of remaining on treatment with lacosamide.Patients with LD presented less AEs than those without LD but a
higher proportion of patients with LD underwent LCS withdrawal,
mainly due to AEs and inefﬁcacy of the drug. However, no
signiﬁcant differences were found comparing those variables (Chi-
squared = 0.213, p = 0.6465 and Chi-squared = 0.005, p = 0.9416,
respectively).
3.3. Idiopathic generalised epilepsy
Thirteen patients with IGE received LCS. Epilepsy in these
patients was highly refractory, they were taking 2.6 AEDs (range 1–
4) on average before starting LCS. The average maximum dose of
LCS was 280 mg/day (range = 100–400). Three patients had a 50%
seizure reduction at an average dose of 200 mg/day. One of these
patients, followed for 27 months, reported a few seizures on some
days with long seizure free periods. Another patient, taking in
addition levetiracetam, clobazam and phenytoin before starting
LCS and followed-up for 8 months, reported no seizures during that
period. Five patients did not experience any change in seizure
frequency, and two had increased seizure frequency. Four patients
stopped LCS, 1 for SEs, 1 because of increasing myoclonic jerks and
two for lack of efﬁcacy.
3.4. Concomitant sodium channel medication
In a subgroup of 116 patients from one centre the outcome at
the ﬁnal FU was compared in patients taking LCS plus another
sodium channel drug verses patients taking LCS plus AEDs with a
different mechanism of action. We also looked for any reduction or
withdrawal of concomitant medications in all patients that
presented some degree of improvement.
The mean age in this group was 41.3 years (range = 17–74); 65
were female; the mean duration of epilepsy was 27.1 years; most
had SPE (92.2%). the mean FU was 10.1 months; 72% had tried at
Table 3
Seizure outcome at 6 months of follow up.
Seizure Type Baseline to ﬁnal 3 months follow up/patient with at least 6 months FU (285) N(%)
50% reduction includimng SF patients 50% reduction Seizure free No response Increase in seizures
All seizures 102(35.7) 62(21.7) 28(9.8) 68(23.8) 53(18.6)
TCS (107) 47(43.9) 15(11.8) 22(20.6) 30(28) 15(14)
CPS (221) 91(41.1) 36(16.2) 31(14) 56(25.3) 38(17.2)
SPS (34) 11(32.3) 9(26.4) 6(17.6) 10(29.4) 4(11.7)
TCS, tonic clonic seizures; CPS, complex partial seizures; SPS, simple partial seizures.
Table 2
Seizure outcome at 3 months of follow up.
Seizure type Baseline to 3 months/patients with at least 3 months FU (347) N%
50% reduction including SF patients 50% reduction Seizure free No response Increase in seizures
All seizures 108 (31.1) 98 (28.2) 32 (9.2) 91 (26.2) 50 (14.4)
TCS (127) 58 (45.7) 20 (15.7) 30 (23.6) 36 (28.3) 13 (10.2)
CPS 268 90 (33.8) 60 (22.6) 31 (11.7) 82 (30.6%) 36 (13.4)
SPS (43) 12 (27.9) 8 (18.6) 5 (11.6) 19 (44.2) 4 (9.3)
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was commenced. The most frequent AEDs were: carbamazepine
(CBZ) 49, levetiracetam (LEV) 48, clobazam (CLB) 32, sodium
valproate (SV) 22, lamotrigine (LMT) 20, topiramate (TPM) 16, and
phenytoin (PHT) 14.
Of these 116 patients, 74 were taking at least one-sodium
channel blocker (PHT, CBZ, oxcarbazepine or LMT). There were no
signiﬁcant differences in the incidence of AEs or of withdrawal of
LCS in the group taking LCS plus another sodium channel blocker in
comparison to LCS plus an AED with a different action (AEs: 24/74
cf. 12/42, Chi-squared = 0.013, p = 0.9081; withdrawal: 22/74 cf.
11/42, Chi-squared = 0.010, p = 0.9218).
Regarding efﬁcacy analysis, patients on sodium channel drugs
were more likely to have 50% seizure reduction and become
seizure free than the patients taking other combination of drugs,
but this difference was again not signiﬁcant; 26/74 compared to
11/42(Chi-squared = 0.273, p = 0.6013), and 15/74 versus 3/42Table 4
Incidence and nature of side effects.
Side effect Total
Sedation/somnolence 89
Dizziness 73
Nausea/gastrointestinal disturbances 56
Unsteadiness 43
Double/blurred vision 42
Headache 32
Skin irritation 13
Weight gain 7
Mood change 6
Confusion/mentally slow 6
Hallucinations 5
Sleep disturbance 5
Slurred speech 5
Pins and needles/numb ﬁngers 4
Memory problems 4
Tremor 3
Depersonalisation/abnormal thoughts 3
Limbs/joints pain 3
Behaviour/verbal aggression 2
Breathless 2
Leg oedema 1
Weakness 1
Reduce appetite 1
Myoclonic jerks 1
Muscle spasm 1
Drooling 1(Chi-squared = 1.863, p = 0.1722), respectively (see Table 5). Of
54(46.5%) patients reporting some degree of improvement in this
group, 12(22.2%) had reduction of other drugs, 2 reduced
carbamazepine and 2 reduced phenytoin. Six (11.1%) discontinued
other medications: 2 levetiracetam, 2 zonisamide, 1 sodium
valproate and 1 tiagabine. None was moved to monotherapy (see
Table 6). Additionally 7 (6%) patients reported improvement in
seizure severity without improvement in seizure frequency.
4. Discussion
This study reﬂects the experience with LCS in 403 patients with
uncontrolled epilepsy in an outpatient setting in 19 hospitals in the
UK and is the largest observational study reported. The patient
population in this project differs from the pivotal studies and other
retrospective and prospective audits in that outcome was assessed
using retention times and we included all patients in whom LCS
had been prescribed and not only those with partial onset seizures.
The study was a retrospective chart review. It was not always
possible to determine the outcome on the basis of exact measures
of seizures numbers. Cases were only recorded as seizure free or
having a 50% plus response if numbers or frequency of seizures
were clearly recorded. Qualitative outcomes such as improved
were assumed to have had only a partial response of less than 50%.
Assessments of no change or worsening were more often based on
overall clinical assessments. Although the same proforma for data
collection was used at each site, a prospective evaluation of
adverse events, including cardiac symptoms or abnormalities in
ECG, was not performed which may have led to these being
underestimated. All cases were however being followed by
specialist epilepsy services and it is unlikely that major or
important adverse events were missed.
Because multiple factors effect retention time and patient
samples vary, comparison with previous studies is difﬁcult. These
results however are broadly in line with three large studies that
have assessed multiple drugs including topiramate, levetiracetam
and zonisamide in large populations.10–12 Lower retention times of
23% at one year have been reported for gabapentin probably
reﬂecting lesser efﬁcacy of this drug as an add on in chronic
epilepsy.10 The higher retention rates of around 75% reported for
lamotrigine 11,12 may be due to the increasing use of this drug as a
long term ﬁrst line medication substituted for other drugs such as
phenytoin or carbamazepine. It is always best therefore to combine
Table 5
Outcome at the last FU in 116 patients taking or not taking concomitant sodium channel drugs.
Characteristic N = 116 Side effects Withdraw 50% seizures reduction ﬁnal FU Seizure free ﬁnal FU
Taking sodium channel drugs (PHT, CBZ, OXC, LMT) 74 24 (32.4%) 22 (29.7%) 26 (35.1%) 15 (20.2%)
Taking other drugs 42 12 (28.5%) 11 (26.1%) 11 (26.1%) 3 (7.1%)
Table 6
Change in concomitant drugs in 54 of 116 patients that improved (116 patients in
whom full AED data were available).
Drug Reduced Removed
Carbamazepine 2
Phenyotin 2
Sodium valproate 1 1
Tiagabine 1 1
Lamotrigine 1
Levetiracetam 1 2
Phenobarbitone 1
Clobazam 1
Primidone 1
Zonisamide 1 2
Total 12 6
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effects on seizure control and adverse events.
Our ﬁnding of a response rate at the ﬁnal FU of 35.7% was
consistent with three pivotal LCS trials which found a median
percentage of patients with 50% seizure reduction of 33.3–34.1%
at LCS 200 mg/day, 36.8–39.7% at 400 mg, and 39.6% at 600 mg.3–
5,13 Our response rate of 32% was also similar to that observed in a
post-marketing study.6 One retrospective study found a 47%
response rate but included only 60 patients.7 The proportion of
patients becoming SF at the last FU in our study was 9.8% (mean
maximum dose 252 mg/day) and greater than 2.4–8% found in
previous studies (mean dose 200–600 mg/day).4,5 However, a
study in Scotland found 26% of patients to be SF (median dose
100 mg/day; range 50–300) for a six months period.8 In this study
the response rate was particularly high in patients using LCS as a
ﬁrst add on medication. The seizure freedom rates in this study are
similar to those previously reported with LEV suggesting good
efﬁcacy.11 Moreover, the average maximum dose of LCS in those
responder patients and those reaching freedom of seizures at the
last FU was reasonably low: 293 mg/day and 239 mg/day
respectively compared to those in the pivotal studies and similar
to other post-marketing published studies.7,9 It is usually the
practice of UK Consultant Neurologists, particularly in patients on
multiple drugs, to titrate slowly and observe the response.
Forty nine percent of patients presented at least one adverse
effect which is higher than most published studies, except for one
post-marketing study that reported a rate of 52%.6 The most
commonly experienced AE in previous controlled and post-
marketing studies was dizziness, followed by nausea, and
vomiting.4,6–8,11,12 In our population sedation was the most
frequent adverse effect, which occurred in 89 patients, followed
by dizziness in 73, and gastrointestinal disturbances in 56. Several
side effects not reported in pre-marketing studies were found in
this and other post marking trials6,8 which could be due to the
larger population studied. These included skin irritation, weight
gain and limb pain. Some neurological and neuropsychiatric side
effects were also reported: paraesthesia, sleep disturbance, slurred
speech, memory problems, tremor, mood change, confusion and
slowness of thinking, hallucinations, depersonalization/abnormal
thoughts, and behaviour problems. In keeping with previous
pivotal studies, audits and service evaluations, the overall
incidence of major neuropsychiatric disorders such as depression
and psychosis appeared to be low, in keeping with the experienceseen in other drugs known to act through the sodium channel.
Cardiac arrhythmias were not reported in the medical notes in any
case.
One hundred and ﬁfty patients (38%) discontinued LCS, most of
them (60%) within six months, mainly due to AEs of sedation and
dizziness. Our rates of discontinuation are considerably higher
than other studies that reported 12.4%8 and 21%,9 28%.6 There is
evidence that combining AEDs that act on sodium channels may be
more likely to produce AEs in comparison to combining AEDs with
different actions.14–17 Novy et al. reported seven patients who
experienced signiﬁcant AEs following the addition of LCS to other
sodium channel blocking AEDs, and suggested that this was
probably due to pharmacodynamic interaction.14 They discussed
the possibility of reducing existing sodium channel blocking AEDs
before introducing LCS to reduce the incidence of AEs. In general,
prospective reduction of concomitant sodium channel co-medica-
tions was not undertaken in our study, which might have
inﬂuenced the results.
It has been suggested that combinations of AEDs with different
mechanisms of action might be more efﬁcacious and/or well
tolerated in comparison to combinations including AEDs with
similar mechanisms of action. This remains an attractive hypothe-
sis on which to attempt to base rational polytherapy. This was lent
some support by a post-marketing study and an analysis that
pooled data from the pivotal LCS studies that found higher
response rates where LCS was combined with non-sodium channel
AEDs.9,18 In our study adding LCS to drugs acting on the sodium
channel was in general more efﬁcacious compared to adding it to
drugs with other mechanisms of action but the ﬁndings were not
statistically signiﬁcant. Both studies were not designed to examine
this question which would require balancing of clinical features in
both treatment groups. Our study did not conﬁrm the notion that
LCS is more efﬁcacious and better tolerated when combined with
non sodium channel agents.
Almost 20% of the patients in this study had LD. The retention
rate of LCS was slightly lower in this group at six months and one
year but at 18 months and two years this rate become similar to
that of patients without LD. The two year ﬁgure was comparable to
that found for LEV in a previous study with a population of similar
characteristics.19 In our study, AEs and reasons for withdrawing
LCS were similar in patients with or without LD. Behavioural side
effects were rare or absent.20 Results from several clinical trials
have shown LCS to be effective for the treatment of partial onset
seizures, but there are no studies in patients with IGE. We found
that 13 patient with IGE were prescribed LCS. Three of these
responded with two presenting long periods of seizure freedom. It
is not possible to draw conclusions regarding any role for LCS in IGE
from our ﬁndings other than that it is worthy of further
investigation.
In conclusion, the results from this study show that LCS is a safe
and effective drug when given as adjunctive therapy in partial-
onset seizures in the general population of patients with epilepsy
and in those with intellectual disabilities.
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